Name: Parsotix's immediate addressable market
Uploaded: 2023-01-19T19:03:08.769369+00:00
Duration: 1403 s
Channel: Master Investor
Description: The near-term return is in pharma services; cancer drug trials can utilise the Parsotix system which offers longitudinal monitoring to patients. Medium- and longer term, the technology provides an opportunity for early diagnosis of high-risk cancer patients as well as for treatment decisions. The total addressable market in the US, which ANGLE focusses on, is $100 billion per annum.

The near-term return is in pharma services; cancer drug trials can utilise the Parsotix system which offers longitudinal monitoring to patients. Medium- and longer term, the technology provides an opportunity for early diagnosis of high-risk cancer patients as well as for treatment decisions. The total addressable market in the US, which ANGLE focusses on, is $100 billion per annum.

The near-term return is in pharma services; cancer drug trials can utilise the Parsotix system which offers longitudinal monitoring to patients. Medium- and longer term, the technology provides an opportunity for early diagnosis of high-risk cancer patients as well as for treatment decisions. The total addressable market in the US, which ANGLE focusses on, is $100 billion per annum.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/004/112/004112/video_pi9sCZf.mov#t=583

Master Investor

Parsotix's immediate addressable market

About ANGLE

ANGLE's initial objective and subsequent focus

ANGLE's Founder's personal motivations

Andrew Newland founded ANGLE PLC (AIM:AGL) in 1994. Twenty-eight years on and his company has won FDA clearance for ANGLE's liquid biopsy Parsortix initiative which in the U.S. alone has a $100 billion per annum addressable market.
 
"We're solving an enormously challenging and important medical question," says Newland who says the ultimate growth of Parsortix is unbounded.

Andrew Newland founded ANGLE PLC (AIM:AGL) in 1994. Twenty-eight years on and his company has won FDA clearance for ANGLE's liquid biopsy Parsortix initiative which in the U.S. alone has a $100 billion per annum addressable market. "We're solving an enormously challenging and important medical question," says Newland who says the ultimate growth of Parsortix is unbounded.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/004/112/004112/video_pi9sCZf.mov

Sarah Lowther quizzes Andrew Newland, CEO of ANGLE, about how his company changes the world in cancer. ANGLE is the only UK listed business to be a leader in the field of liquid biopsy for personalised cancer treatment. The company is listed on AIM and had a market cap of £321 million as of May 2022.

ANGLE was founded in 1994 with the initial objective of establishing one or more world-class companies based on intellectual property. It was listed in 2004, and eventually identified Parsotix Inc. as one of its standout companies to focus on, based on its potential to improve cancer patients' lives, and its risk/return position. For over ten years, ANGLE has been focussing exclusively on developing Parsotix further.

For Founder and Chief Executive Andrew Newland, making a difference to cancer patients around the world is key; ANGLE provides the unprecedented ability to assess patients' cancer from a blood sample only. Newland urges other researchers to use the FDA-cleared platform to develop methodologies to improve outcomes for breast cancer patients.